The march toward rational therapeutics in children

Area of Science:

• Pediatric pharmacology
• Drug regulation
• Child health outcomes

Background:

• Children experience numerous diseases similar to adults.
• Most drugs lack FDA approval for pediatric use.
• This necessitates off-label prescribing and poses risks.

Purpose of the Study:

• To review the progress in pediatric drug labeling over the past 25 years.
• To highlight the challenges in ensuring adequate pediatric treatment.
• To underscore the importance of approved labeling for child safety.

Main Methods:

• Literature review of pediatric drug approval and labeling.
• Analysis of regulatory changes and their impact.
• Examination of clinical practice challenges.

Main Results:

• Progress in pediatric labeling has been slow over the last two and a half decades.
• Significant gaps remain in approved medications for pediatric populations.
• Physicians often lack comprehensive labeling information for pediatric use.

Conclusions:

• Improved pediatric drug labeling is crucial for optimal child protection.
• Continued efforts are needed to expand approved treatment options for children.
• Addressing labeling deficiencies enhances therapeutic range and safety.